4-hexylresorcinol administration supresses p53 mutant oral cancer cells via epigenetic moification
- 저자식별ID ORCID:0000-0002-6984-5234
- 발행기관 강릉원주대학교 일반대학원
- 발행년도 2021
- 학위수여년월 2022. 2
- 학위명 박사
- 학과 및 전공 도움말 일반대학원 치의학과
- 실제URI http://www.dcollection.net/handler/kangnung/000000011067
- UCI I804:42001-000000011067
- 본문언어 영어
초록/요약 도움말
Objective: p53 mutation is inherent in over 50% of human cancer. In head and neck squamous cell carcinoma, p53 mutation has associated with a poor prognosis. The aim of this study was to investigate the effect of 4-Hexylresorcinol (4HR) on p53 mutant mucoepidermoid carcinoma cells (YD-15) and its therapeutic effects in xenograft model. Material and methods: To determine the effect of 4HR on p53 mutant mucoepidermoid carcinoma cells (YD-15), western blot analysis, p53 transcription activity, MTT assay, and apoptosis immunocytochemistry were done. The effect was also evaluated in xenograft study. Results: In the cell experiments, when the 4HR concentrations increased, the expression level of HDAC4, acetylated p53(Ac-p53), phosphorylated p53(p-p53) increased. Increased p53 transcription activity and decreased cell viability, and increased apoptosis were observed. When treated 4HR to xenograft model compared with control (β-cyclodextrin), the tendency of tumor expansion rate was suppressed and exihibited higher survival rate. In early period, there was less body weight loss in 4HR group. In the immunohistochemical analysis, the 4HR group had higher expression HDAC4, acetyl-p53, p-p53 compared to the control group, The result of protein array of blood serum was that 4HR partially reduced apoptosis and the systemic effect of 4HR could reduce side effects. Conclusion: 4HR is a potential substance to recover the loss of function in mutant p53 via acetylation of p53 with HDAC4 inhibition and phosphorylation of p53.
more목차 도움말
Ⅰ. Introduction 1page
Ⅱ. Material and Methods 2page
Ⅲ. Results 6page
Ⅳ. Discussion 9page
Ⅴ. Conclusion 12page
Ⅵ. References 13page
